Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.semarthrit.2019.06.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies.
Front Immunol
December 2024
Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, United States.
Introduction: Immunogenicity continues to be a challenge for development and clinical utility of monoclonal antibodies, and there are gaps in our current ability to prevent anti-drug antibody development in a safe and antigen-specific manner.
Methods: To mitigate immunogenicity of monoclonal antibodies administered subcutaneously, O-phospho-L-serine (OPLS)-the head group of the tolerance-inducing phospholipid, phosphatidylserine-was investigated as an immunoregulatory adjuvant.
Results: Formulations of adalimumab, trastuzumab or rituximab with OPLS showed reduction in relative immunogenicity in mice compared to vehicle formulations, indicated by reduced anti-drug antibody development and significant reductions in CD138+ plasma cell differentiation in bone marrow.
Quality of life and clinical gout assessments during pegloticase with and without methotrexate co-therapy: MIRROR randomized controlled trial exploratory findings.
Rheumatol Adv Pract
November 2024
Rheumatology, Western Washington Arthritis Clinic, Bothell, WA, USA.
Article Synopsis
- Pegloticase effectively lowers serum urate levels in patients with uncontrolled gout, but its use is limited by the development of anti-drug antibodies.
- Co-administration of methotrexate (MTX) was found to enhance the urate-lowering response and reduce the risk of infusion reactions, benefiting patients with limited treatment options.
- In a study involving 100 patients, those receiving pegloticase and MTX showed greater improvements in gout response rates compared to those receiving pegloticase and a placebo after 52 weeks of treatment.
Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial.
PLoS Med
October 2024
Harvard Medical School, Sean M. Healey & AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Background: The interaction of CD40L and its receptor CD40 on activated T cells and B cells respectively control pro-inflammatory activation in the pathophysiology of autoimmunity and transplant rejection. Previous studies have implicated signaling pathways involving CD40L (interchangeably referred to as CD154), as well as adaptive and innate immune cell activation, in the induction of neuroinflammation in neurodegenerative diseases. This study aimed to assess the safety, tolerability, and impact on pro-inflammatory biomarker profiles of an anti CD40L antibody, tegoprubart, in individuals with amyotrophic lateral sclerosis (ALS).
View Article and Find Full Text PDFThree-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Inflamm Bowel Dis
October 2024
Department of Medicine I, Agaplesion Markus Krankenhaus, Frankfurt, Germany.
Background: Mirikizumab, a p19-directed interleukin-23 monoclonal antibody, has demonstrated induction of clinical remission at week 12 with maintenance through week 104 in patients with moderately-to-severely active ulcerative colitis (UC). Results are presented from the LUCENT-3 open-label extension study through week 152.
Methods: Of 868 LUCENT clinical trial program mirikizumab-treated induction patients, 544 were responders of whom 365 were rerandomized to mirikizumab maintenance.
Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease.
Aliment Pharmacol Ther
November 2024
Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Article Synopsis
- There are many treatment options for inflammatory bowel disease (IBD), but the current standard doses often don't meet the desired results, highlighting the need to improve existing therapies instead of only focusing on new ones.
- The article emphasizes the use of therapeutic drug monitoring (TDM) to enhance the effectiveness of biologic therapies, particularly for TNF inhibitors, by measuring drug levels and identifying immune reactions.
- By optimizing dosages and maintaining appropriate drug levels, patients have a better chance of achieving sustained clinical remission beyond just symptom management.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!